Tata-backed MedTherapy claims CAR-T breakthrough with one-day production

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can reduce production time from several weeks to just one day and cut costs by nearly 70%, potentially making advanced cancer treatment more affordable.